BridgeBio Oncology Therapeutics (BBOT) Current Leases (2025 - 2026)

BridgeBio Oncology Therapeutics (BBOT) posted Current Leases of $538000.0 for Q1 2026, up 3.07% sequentially from $522000.0 in Q4 2025.

BridgeBio Oncology Therapeutics (BBOT) Current Leases (2025 - 2026) Analysis & Trends

BridgeBio Oncology Therapeutics has reported Current Leases for 2 years, with the latest figure at $538000.0 in Q1 2026.

Quarterly Current Leases changed N/A year-over-year to $538000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $538000.0 (changed N/A YoY) and the FY2025 annual result came in at $522000.0, changed N/A from the prior year.
Current Leases climbed to $538000.0 in Q1 2026 per BBOT's latest filing, from $522000.0 in the prior quarter.
Over five years, Current Leases peaked at $538000.0 in Q1 2026 and troughed at $506000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Leases (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	720.00 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	11.00 Mn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	16.75 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	21.95 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	2.24 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	45.93 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	6.27 Mn
10	BridgeBio Oncology Therapeutics	726.38 Mn	500.67 Mn	-	554,000.00

Download Data